Why the study?
What are the maximum venous concentrations and safety profile of bupivacaine administered via different dosing regimens for axillary plexus block in patients undergoing upper extremity surgery?
What are the maximum venous concentrations and safety profile of bupivacaine administered via different dosing regimens for axillary plexus block in patients undergoing upper extremity surgery?
High doses of bupivacaine in axillary plexus block result in elevated venous concentrations but appear safe without observable toxic side-effects during the block or recovery.
Answers are grounded in this paper and cite their sources.
Bupivacaine levels stayed subtoxic without side-effects in this case; hypothesis-generating and leaves open safety in larger populations.
The material consisted of 25 patients undergoing orthopaedic or plastic surgery of the upper extremity, including seven cases of replantation surgery. The total doses of bupivacaine, 150-267 mg as a single dose, 280-440 mg as a supplementary dose and 247-629 mg as a continuous infusion, resulted in maximum venous concentrations of 0.68-3.33 micrograms/ml, 1.21-2.44 micrograms/ml and 0.51-1.89 micrograms/ml, respectively. These usually occurred 30-60 min after the injection of bupivacaine and always following the second injection when a supplementary dose was needed. The highest individual value noted occurred 15 min after single injection, possibly as a result of an exceptionally rapid absorption. Despite the high doses and the rather high venous peak concentration of bupivacaine in some of the patients, no toxic side-effects were observed during the block or during the recovery period.
No takes yet. Share an insight, caveat, or question.
Tuominen et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: